1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Commercial Potential of the Forthcoming US Biosimilars Market 

Commercial Potential of the Forthcoming US Biosimilars Market 

  • February 2014
  • -
  • Frost & Sullivan
  • -
  • 156 pages

An Addendum to “Specialty Physicians Discuss their Opinions of the United States Biosimilars Market”

Executive Summary

•The arrival of biosimilars, or highly similar copies of biopharmaceutical products, to the US market is imminent. Although the products have been available elsewhere—including Europe—for several years, physicians and other key stakeholders in the United States have only recently begun to anticipate their arrival.
•This panel discussion was conducted to preview the thoughts and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors that could influence market uptake.
•Based on this representative sample of physicians, the overall adoption of biosimilars can be expected to experience a widespread uptake due to anticipated access to comparable therapeutic options at a lower cost versus high-cost biologics. Main factors with the potential to influence the rate and extent of uptake include cost, safety and efficacy data including testing in specific patient populations, and reputation of the manufacturer.
•Potential skepticism may be overcome with the help of convincing noninferiority clinical data for products from reputable companies that are highly experienced with biologics. Educational programs deemed to be unbiased that convey this data could help increase awareness and boost physician confidence in biosimilar products.

Objective

Frost & Sullivan assessed physicians’ willingness to prescribe biosimilars in the United States.
The objective of this research was to conduct a highly qualitative analysis of a representative sample of practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion.
The primary goal was to encourage participants to freely express their opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market.
This research was not intended to produce quantitative data.

Methodology

The biosimilar research panel consisted of preselected participants and was conducted via online moderated discussion boards over a three-day period (October 11-13, 2011). A series of questions was asked on current topics of interest to specialty physicians as well as pharmaceutical and biotechnology companies. Questions and discussions were designed to gauge both short-term and long-term trends and impacts.

Participants

The panel consisted of specialty physicians: seven oncologists, seven rheumatologists, and 6 hematologists. Panel participants were randomly selected from a pool of prescreened, qualified candidates and mainly represented hospitals and independent practices across the United States. Selection of specialty practices was based on the therapy area of those biosimilar agents anticipated to enter the US market in the foreseeable future.

Biopharmaceuticals and Biosimilars

•Biopharmaceuticals represent one of the most important innovations in medical history. However, these breakthrough therapies are extremely costly, owing to the magnitude of investment necessary in their discovery and development, driving a need for less-costly alternatives.
•While current regulations allow for the approval of generic copies of conventional pharmaceuticals at greatly reduced costs, until recently there has not been the technology nor regulatory pathway with which to introduce lower-cost versions of biologics.
•The US Congress has recently enacted legislation to enable and encourage the introduction of biosimilars/follow-on biologics, paving the way into an untapped market.
•However, many obstacles to a clear abbreviated regulatory pathway and market uptake in the US remain, such as guidance regarding clinical research requirements, naming convention, and end-user acceptance to name a few.
•While sponsors await final guidance from the Food and Drug Administration (FDA), Eli Lilly, and Boehringer Ingelheim have opted to file LY2963016, a biosimilar version of Sanofi’s Lantus (insulin glargine) through the 505(b)(2) pathway, and the application was recently accepted by the FDA in December 2013.

Table Of Contents

Commercial Potential of the Forthcoming US Biosimilars Market 
Executive Summary
Introduction
Background Briefing
Physician Prescribing Behavior
Customer Purchasing Behavior
Regulatory Environment
Biosimilar Manufacturers
Appendix
•Online Discussion Board Transcripts
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.